Asthma Therapeutics

Global Asthma Therapeutics Market to Reach US$21.6 Billion by 2030

The global market for Asthma Therapeutics estimated at US$18.9 Billion in the year 2024, is expected to reach US$21.6 Billion by 2030, growing at a CAGR of 2.3% over the analysis period 2024-2030. Anti-Inflammatory Drugs, one of the segments analyzed in the report, is expected to record a 2.5% CAGR and reach US$10.7 Billion by the end of the analysis period. Growth in the Combination Therapy segment is estimated at 2.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.1 Billion While China is Forecast to Grow at 3.3% CAGR

The Asthma Therapeutics market in the U.S. is estimated at US$5.1 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$4.1 Billion by the year 2030 trailing a CAGR of 3.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.8% and 1.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.1% CAGR.

Global Asthma Therapeutics Market - Key Trends and Drivers Summarized

How Are Asthma Therapeutics Evolving in Response to Rising Global Demand?

Asthma therapeutics have undergone significant evolution in response to the growing prevalence of asthma worldwide, driven by factors such as increasing pollution, urbanization, and changing lifestyles. Asthma is a chronic respiratory condition that affects millions globally, requiring ongoing management and treatment to prevent severe exacerbations. Traditionally, asthma management has relied heavily on inhaled corticosteroids (ICS) and bronchodilators, which remain foundational in controlling symptoms and preventing attacks. However, as our understanding of asthma’s underlying mechanisms has advanced, so too have the therapeutic options. Today, the asthma therapeutics landscape is expanding with the introduction of biologics, targeted therapies, and innovative delivery systems that offer more personalized and effective treatment options. These advancements are transforming asthma care, making it possible to tailor treatments to individual patient needs, improve adherence, and reduce the burden of the disease.

What Role Do Technological Innovations Play in Advancing Asthma Treatment?

Technological innovations are playing a pivotal role in advancing asthma treatment, particularly through the development of smart inhalers and digital health solutions. Smart inhalers, which are equipped with sensors to track medication use and monitor environmental triggers, are helping patients manage their asthma more effectively by providing real-time data and reminders to improve adherence. These devices are part of a broader trend towards digital health in asthma management, where mobile apps and telemedicine platforms are increasingly used to monitor symptoms, adjust treatment plans, and connect patients with healthcare providers remotely. Additionally, advancements in inhaler technology, such as the development of soft mist inhalers and breath-actuated devices, are improving drug delivery efficiency and patient experience. The integration of artificial intelligence (AI) in predicting asthma attacks and customizing treatment regimens is another area of significant progress. These technological innovations are not only enhancing the efficacy of asthma therapeutics but are also empowering patients with tools to take greater control of their condition.

Which Market Trends Are Driving the Adoption of Advanced Asthma Therapeutics?

Several market trends are driving the adoption of advanced asthma therapeutics, reflecting broader changes in healthcare delivery and patient expectations. The growing focus on personalized medicine is one of the most significant trends, with biologics and targeted therapies becoming increasingly prominent in the treatment of severe asthma. These treatments, such as monoclonal antibodies that specifically target the inflammatory pathways involved in asthma, are offering new hope to patients who do not respond well to traditional therapies. Another trend is the increasing importance of preventive care, as healthcare systems worldwide shift towards reducing the long-term burden of chronic diseases like asthma. This has led to greater emphasis on long-term control medications and strategies aimed at preventing asthma exacerbations before they occur. Additionally, the rising awareness of asthma among patients and healthcare providers, coupled with the expansion of telemedicine, is driving more proactive and continuous management of the condition. These trends underscore a broader shift towards more comprehensive, individualized, and technology-enabled asthma care.

What Factors Are Driving the Growth of the Asthma Therapeutics Market?

The growth in the asthma therapeutics market is driven by several factors that are reshaping the landscape of asthma care. A key driver is the rising prevalence of asthma globally, particularly in urban areas where pollution and other environmental factors are exacerbating respiratory conditions. Technological advancements, such as the development of smart inhalers and digital health platforms, are also propelling market growth by improving treatment adherence and enabling more personalized care. The increasing availability of biologics and targeted therapies is expanding treatment options for patients with severe asthma, addressing unmet needs in the market and driving demand for these advanced therapies. Additionally, the expansion of healthcare coverage and government initiatives to improve access to asthma medications are playing a crucial role in market growth, particularly in emerging markets where access to advanced treatments has been limited. As these factors continue to influence the market, the asthma therapeutics industry is poised for sustained growth, driven by innovation, increasing patient awareness, and the growing need for effective asthma management solutions.

SCOPE OF STUDY:

The report analyzes the Asthma Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Drug Class (Anti-Inflammatory Drugs, Combination Therapy, Bronchodilators); Treatment Type (Long-Term Asthma Control Medications, Quick-Relief Medications); Route of Administration (Inhalation, Parenteral, Oral)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• ALK-Abello AS
• Amgen, Inc.
• Array BioPharma, Inc.
• Astellas Pharma, Inc.
• AstraZeneca PLC
• Atopix Therapeutics Ltd.
• Boehringer Ingelheim International GmbH
• CareFusion Corporation
• Chiesi Farmaceutici SpA
• Dynavax Technologies Corporation
• F. Hoffmann-La Roche AG
• GlaxoSmithKline PLC
• Horizon Pharma PLC
• Invion Ltd.
• Kissei Pharmaceutical Co., Ltd.
• Kyowa Hakko Kirin Co., Ltd.
• MediciNova, Inc.
• Merck & Co., Inc.
• Mitsubishi Tanabe Pharma Corporation
• Mundipharma International Limited
• Oxagen Ltd.
• Palobifarma S.L.
• Pharmaking Co., Ltd.
• Pharmaxis Ltd.
• Philips Healthcare
• Regeneron Pharmaceuticals, Inc.
• Revalesio Corporation
• Roche Diagnostics (Schweiz) AG
• SAMA Pharm Co., Ltd.
• Sanofi
• Skyepharma Production SAS
• SolAeroMed Inc.
• Stallergenes Greer
• Sterna Biologicals GmbH & Co. KG
• Sunovion Pharmaceuticals, Inc.
• Synairgen Plc
• Teva Pharmaceutical Industries Ltd.
• Theron Pharmaceuticals Inc.
• UCB SA
• Vectura Group PLC
• Verona Pharma Plc
• WHANIN Pharmaceutical Co., Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs CBob geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.